KR-20260064916-A - Composition for diagnosing emphysema in asthma and COPD comprising MYH10

Abstract

The present invention relates to a composition for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema, and a method for providing information necessary for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema using the same. Since the degree of emphysema, which is difficult to assess with conventional chest radiography, can be identified when the plasma MYH10 expression level is increased compared to a normal control group as a result of measuring the plasma MYH10 expression level using the diagnostic composition according to the present invention, it can be usefully used to effectively predict or diagnose the degree of asthma, chronic obstructive pulmonary disease, and emphysema, as well as the early diagnosis, with high sensitivity and specificity.

Inventors

• 장안수
• 이푸른하늘
• 안민혁

Assignees

• 순천향대학교 산학협력단

Dates

Publication Date

20260508

Application Date

20241030

Claims (10)

1. A composition for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema, comprising a preparation capable of measuring the expression level of the MYH10 (Myosin heavy chain 10) gene.
2. A composition for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema, wherein, in claim 1, the expression level of the MYH10 gene is measured in whole blood, plasma, or serum samples isolated from an individual.
3. A composition for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema, wherein, in claim 1, the expression level of the MYH10 gene is the mRNA expression level of the MYH10 gene containing the nucleotide sequence represented by SEQ ID NO. 1, or the expression level of a protein containing the amino acid sequence represented by SEQ ID NO. 2.
4. A composition for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema, wherein the composition is intended to diagnose emphysema in an individual suffering from asthma or chronic obstructive pulmonary disease.
5. A composition for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema, wherein the preparation capable of measuring the expression level of the MYH10 gene is a monoclonal antibody, polyclonal antibody, chimeric antibody, or an antigen-binding fragment thereof, a ligand, a PNA (Peptide nucleic acid), or an aptamer that specifically binds to a protein encoded by the MYH10 gene.
6. A composition for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema, wherein, in claim 1, the preparation capable of measuring the expression level of the MYH10 gene is a primer pair, a probe, or an antisense nucleotide that specifically binds to the gene.
7. A diagnostic kit for asthma, chronic obstructive pulmonary disease, or emphysema comprising the composition of any one of claims 1 to 6.
8. A method for providing information necessary for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema, comprising the step of measuring the expression level of the MYH10 gene in a sample isolated from a subject.
9. A method for providing information necessary for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema, wherein, in claim 8, the sample separated from the subject is whole blood, plasma, or serum.
10. A method for providing information necessary for the diagnosis of asthma, chronic obstructive pulmonary disease, or emphysema, wherein, in claim 8, the method further comprises the step of determining asthma, chronic obstructive pulmonary disease, or emphysema when the expression level of the MYH10 gene is increased compared to the expression level measured in a sample isolated from a normal individual.

Description

Composition for diagnosing emphysema in asthma and chronic obstructive pulmonary disease comprising MYH10 and use thereof The present invention relates to a composition for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema, and a method for providing information necessary for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema using the same. Emphysema is a disease characterized by the abnormal expansion of the air space below the terminal bronchioles and the destruction of alveolar walls, which leads to a decrease in elastic recoil pressure and causes irreversible airway obstruction during exhalation. Since emphysema is difficult to detect with simple radiography, it is diagnosed using High Resolution Computed Tomography (HRCT), which assigns an emphysema score to the degree of air space expansion. Myosin-10, also known as myosin heavy chain 10 or non-muscle myosin IIB (NM-IIB), is a protein encoded by the human MYH10 gene and is a cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. It plays an important role in cytoskeletal reorganization, focal contact formation (present in the center of the spreading cell but absent at the edges), and lamellipodial extension during cell spreading. MYH10 expression levels have been shown to be associated with extracellular matrix and lung disease in patients with many types of emphysema. Specifically, MYH10 is involved in alveolar formation and contributes to the pathogenesis of emphysema. However, the precise role of MYH10 in Chronic Obstructive Pulmonary Disease (COPD) has not yet been determined. A method for providing information for the diagnosis of asthma by measuring the expression level of plasma claudin 4 protein has been disclosed in Korean Registered Patent No. 10-1754490, and a biomarker composition for diagnosing acute exacerbation of chronic obstructive pulmonary disease by measuring the expression levels of 35 proteins, including keratin 10 and myosin-9, has been disclosed in Korean Registered Patent No. 10-1274835. However, a composition for diagnosing asthma, chronic obstructive pulmonary disease, or emphysema by measuring the expression level of MYH10 protein has not been disclosed. FIG. 1a is a figure showing the protein expression levels of the MYH10 gene measured by ELISA in the plasma of a normal control group, an asthma patient group, and a chronic obstructive pulmonary disease (COPD) patient group according to one embodiment of the present invention. In the graph, ○ indicates individuals without emphysema, and △ indicates individuals with emphysema. FIG. 1b is a graph showing the number of patients with negative or positive emphysema in an asthma patient group and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. Figure 2a is a figure confirming the positive correlation between plasma MYH10 expression levels and neutrophils in a normal control group and a patient group with chronic obstructive pulmonary disease according to one embodiment of the present invention. FIG. 2b is a figure confirming the negative correlation between plasma MYH10 expression levels and lymphocytes in a normal control group and a patient group with chronic obstructive pulmonary disease according to one embodiment of the present invention. FIG. 2c is a figure confirming the negative correlation between plasma MYH10 expression levels and FVC % pred. in a normal control group and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. Figure 3a is a figure confirming the negative correlation between plasma MYH10 expression levels and BMI in an asthma patient group and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. FIG. 3b is a figure confirming the negative correlation between plasma MYH10 expression levels and FEV1 1 % pred. in an asthma patient group and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. FIG. 3c is a figure confirming the negative correlation between plasma MYH10 expression levels and FVC% pred. in an asthma patient group and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. FIG. 3d is a figure confirming the negative correlation between plasma MYH10 expression levels and FEV1 /FVC in an asthma patient group and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. Figure 4 is a figure showing the results of ROC curve analysis for MYH10 levels in a normal control group, an asthma patient group, and a chronic obstructive pulmonary disease patient group according to one embodiment of the present invention. The present invention will be explained in more detail below through the following examples. However, thes